Medarex - Antibodies as Therapeutics

Using fully human monoclonal antibodies, we believe it is possible to reduce the time and cost of drug development. Additionally, because human monoclonal antibodies are natural proteins, we believe they are likely to be less toxic, and more effective, than the chemical drugs used to treat cancer and other life-threatening diseases. Accordingly, fully human monoclonal antibodies represent a uniquely efficient and effective way to turn genomic discoveries into therapeutic products.

Type	Product	Marketer	Approved

Murine	Orthoclone OKT3 Allograft rejection	Johnson & Johnson	June 1986

Chimeric	ReoPro PTCA adjunct	Lilly	December 1994

Chimeric	Rituxan Non-Hodgkin's lymphoma	Genentech	November 1997

Chimeric	Simulect Organ rejection prophylaxis	Novartis	May 1998

Chimeric	Remicade Rheumatoid arthritis, Crohn's disease	Johnson & Johnson	August 1998

CDR-grafted	Zenapax Organ rejection prophylaxis	Roche	December 1997

CDR-grafted	Synagis Respiratory syncytial virus (RSV)	Medimmune	June 1998

CDR-grafted	Herceptin Metastatic breast cancer	Genentech	September 1998

CDR-grafted	Mylotarg Acute myeloid leukemia	Wyeth	May 2000

CDR-grafted	Campath Chronic lymphocytic leukemia	Millennium	July 2001

Murine Radiolabeled	Zevalin Non-Hodgkin's Lymphoma (relapsed or refractory low-grade, follicular, or transformed B cell)	IDEC Pharmaceuticals and Schering AG	March 2002

Phage Display	Humira Rheumatoid arthritis	Abbott Laboratories	December 2002

CDR-grafted	Xolair Moderate to severe persistent asthma	Genentech and Novartis	June 2003

Murine Radiolabeled	Bexxar CD20 positive, follicular, Non-Hodgkin's Lymphoma (NHL)	Corixa and GlaxoSmithKline	June 2003

CDR-grafted	Raptiva Chronic moderate-to-severe psoriasis	Genentech and Xoma	October 2003

Chimeric	Erbitux Colorectal cancer	Imclone and Bristol-Myers Squibb	February 2004

CDR-grafted	Avastin Colorectal cancer	Genentech	February 2004

CDR-grafted	Tysabri Multiple sclerosis	Biogen-Idec and Elan	November 2004

CDR-grafted	Lucentis (ranibizumab) Wet age-related macular degeneration	Genentech	June 2006

Transgenic	Vectibix (panitumumab) Colorectal cancer	Amgen / Abgenix	September 2006

CDR-grafted	Soliris (eculizumab) Paroxysmal nocturnal hemoglobinuria	Alexion	March 2007
These monoclonal antibody products are marketed by the companies listed and are not in any way connected with Medarex except as may be disclosed from time to time in the public filings of Medarex with the SEC.